Skip to content
10-Q

Quarterly Report

AYTU BIOPHARMA, INC AYTU

0001437749-26-016721

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · Apr 30, 2026 10.73M sh
Shares Diluted Q3 2026 · Mar 31, 2026 10.51M sh
Shares Diluted Q3 2026 · Mar 31, 2026 9.99M sh
Shares Diluted Q3 2026 · Mar 31, 2025 8.2M sh
Shares Diluted Q3 2026 · Mar 31, 2025 8.61M sh
Capex Q3 2026 · Mar 31, 2026 $17K
Capex Q3 2026 · Mar 31, 2025 $211K
Operating Cash Flow Q3 2026 · Mar 31, 2026 −$1.13M
Operating Cash Flow Q3 2026 · Mar 31, 2025 −$4.74M
Long Term Debt Q3 2026 · Mar 31, 2026 $9.55M
Cash And Equivalents Q3 2026 · Mar 31, 2026 $26.72M
Cash And Equivalents Q3 2026 · Jun 30, 2025 $30.95M
Stockholders Equity Q3 2026 · Mar 31, 2026 $35.14M
Stockholders Equity Q3 2026 · Dec 31, 2025 $14.2M
Stockholders Equity Q3 2026 · Sep 30, 2025 $23.17M
Stockholders Equity Q3 2026 · Jun 30, 2025 $18.97M
Stockholders Equity Q3 2026 · Mar 31, 2025 $34.9M
Stockholders Equity Q3 2026 · Dec 31, 2024 $30.77M
Stockholders Equity Q3 2026 · Sep 30, 2024 $29.83M
Stockholders Equity Q3 2026 · Jun 30, 2024 $27.72M
Current Liabilities Q3 2026 · Mar 31, 2026 $59.97M
Current Liabilities Q3 2026 · Jun 30, 2025 $63.06M
Current Assets Q3 2026 · Mar 31, 2026 $67.33M
Current Assets Q3 2026 · Jun 30, 2025 $79.18M
Total Assets Q3 2026 · Mar 31, 2026 $111.69M
Total Assets Q3 2026 · Jun 30, 2025 $124.18M
Eps Diluted Q3 2026 · Mar 31, 2026 −$0.53
Eps Diluted Q3 2026 · Mar 31, 2026 −$1.42
Eps Diluted Q3 2026 · Mar 31, 2025 $0.21
Eps Diluted Q3 2026 · Mar 31, 2025 −$0.22
Eps Basic Q3 2026 · Mar 31, 2026 −$0.53
Eps Basic Q3 2026 · Mar 31, 2026 −$1.42
Eps Basic Q3 2026 · Mar 31, 2025 $0.65
Eps Basic Q3 2026 · Mar 31, 2025 $1.02
Rd Expense Q3 2026 · Mar 31, 2026 $0
Rd Expense Q3 2026 · Mar 31, 2026 $0
Rd Expense Q3 2026 · Mar 31, 2025 $162K
Rd Expense Q3 2026 · Mar 31, 2025 $1.11M
Net Income Q3 2026 · Mar 31, 2026 −$5.62M
Net Income Q3 2026 · Mar 31, 2026 −$14.24M
Net Income Q3 2026 · Dec 31, 2025 −$10.58M
Net Income Q3 2026 · Sep 30, 2025 $1.97M
Net Income Q3 2026 · Mar 31, 2025 $3.99M
Net Income Q3 2026 · Mar 31, 2025 $6.26M
Net Income Q3 2026 · Dec 31, 2024 $788K
Net Income Q3 2026 · Sep 30, 2024 $1.47M
Operating Income Q3 2026 · Mar 31, 2026 −$4.06M
Operating Income Q3 2026 · Mar 31, 2026 −$7.54M
Operating Income Q3 2026 · Mar 31, 2025 $2.42M
Operating Income Q3 2026 · Mar 31, 2025 −$204K
Gross Profit Q3 2026 · Mar 31, 2026 $7.6M
Gross Profit Q3 2026 · Mar 31, 2026 $26.41M
Gross Profit Q3 2026 · Mar 31, 2025 $12.81M
Gross Profit Q3 2026 · Mar 31, 2025 $35.58M
Revenue Q3 2026 · Mar 31, 2026 $12.41M
Revenue Q3 2026 · Mar 31, 2026 $41.46M
Revenue Q3 2026 · Mar 31, 2025 $18.45M
Revenue Q3 2026 · Mar 31, 2025 $51.25M